17 years biotech experience in the areas of process development, manufacturing, program management and business development. Served as the strategic and technical lead for neurotoxin programs at Allergan, which include next generation neurotoxin molecules. Formerly at Regeneron and Baxter.
WAJDIE AHMAD, MBA
Chief Operating Officer, Co-Founder
16 years of biotech experience, a majority of which is at Allergan focusing on the development, characterization, and manufacturing of neurotoxin drug substance, which includes BOTOX®. Patent holder for botulinum neurotoxin manufacturing processes.
SUSAN ABUSHAKRA, M.D.
Chief Medical Officer, Co-Founder
15 years of drug development experience, in addition to being a board certified neurologist, with residency and neuromuscular/ neurophysiology specialty training from Johns Hopkins. Previously, Chief Medical Officer at Elan/Perrigo and Vice President, Global Drug Development at Allergan, where led several clinical development programs for BOTOX® and other neurotoxin products.
MIKE JARPE, Ph.D.
Executive Vice President, Drug Development, Co-Founder
25 years of biotech and pharmaceutical experience in multiple therapeutic areas including biologics, cell therapies, small molecules, and combination products. Served as Vice President Biologics development at Allergan, leading product development activities for all neurotoxin programs. Formerly at Eisai, RenaMed, Cambridge Neuroscience, and Baxter.
20 years of experience developing novel therapeutics, including biologics, small molecules, and drug-device combinations. Served in senior leadership roles in technical operations and global regulatory affairs in the U.S. and Europe, focusing on pharmaceutical development strategy across a range of therapeutic areas. Formerly at Allergan, Amgen, Gilead Sciences, Micromet, among others.